Table 5.
Three- and 5-year OS and 95% CI for pN stage and mpN stage in the training and validation cohorts.
| Variables | No. of patients (%) | HR (95% CI) | 3-Y OS (%) | 5-Y OS (%) | P value* |
|---|---|---|---|---|---|
| Training cohort | |||||
| pN stage | <0.001 | ||||
| pN1a | 2,079 (32.3) | 1 (Reference) | 88.7 | 81.0 | |
| pN1b | 2,030 (31.5) | 1.346 (1.182–1.534) | 84.6 | 75.2 | |
| pN1c | 273 (4.2) | 1.365 (1.057–1.762) | 84.5 | 75.5 | |
| pN2a | 1,191 (18.5) | 1.853 (1.612–2.129) | 78.3 | 67.6 | |
| pN2b | 867 (13.5) | 3.134 (2.733–3.594) | 63.7 | 51.1 | |
| mpN stage | <0.001 | ||||
| mpN1a | 1,948 (30.2) | 1 (Reference) | 89.1 | 81.7 | |
| mpN1b | 2,126 (33) | 1.331 (1.163–1.522) | 85.0 | 76.3 | |
| mpN2a | 1,172 (18.2) | 1.816 (1.570–2.100) | 79.7 | 69.2 | |
| mpN2b | 1,065 (16.5) | 2.941 (2.566–3.372) | 67.8 | 55.3 | |
| mpN2c | 129 (2) | 4.279 (3.346–5.474) | 60.0 | 40.1 | |
| Validation cohort | |||||
| pN stage | <0.001 | ||||
| pN1a | 909 (33) | 1 (Reference) | 86.4 | 78.3 | |
| pN1b | 826 (29.9) | 1.272 (1.055–1.534) | 81.9 | 72.3 | |
| pN1c | 140 (5.1) | 1.356 (0.966–1.901) | 82.9 | 70.2 | |
| pN2a | 504 (18.3) | 1.656 (1.357–2.021) | 78.3 | 65.5 | |
| pN2b | 379 (13.7) | 2.184 (1.779–2.682) | 67.2 | 57.7 | |
| mpN stage | <0.001 | ||||
| mpN1a | 850 (30.8) | 1 (Reference) | 86.9 | 79.9 | |
| mpN1b | 900 (32.6) | 1.349 (1.114–1.633) | 82.4 | 72.5 | |
| mpN2a | 525 (19) | 1.779 (1.451–2.181) | 79.3 | 65.6 | |
| mpN2b | 425 (15.4) | 2.180 (1.769–2.685) | 69.8 | 60.4 | |
| mpN2c | 58 (2.1) | 3.674 (2.547–5.300) | 58.6 | 39.7 |
CI, confidence interval; HR, hazard ratios; mpN, modified pathological N; No., number; OS, overall survival; pN, pathological N; Y, year.
*P value based on log-rank test.